Stryker investors not fazed by spinal device recall
This article was originally published in Clinica
Executive Summary
Stryker has been slapped with a Class I recall from the US FDA for a component of its OASYS occipito-cervico-thoracic system, designed to aid spinal fusion. But the firm’s share price barely seemed to be affected, closing flat at $66.91 on 29 August, the day the FDA posted news of the recall on its website.